Comments have been submitted by AdvaMed and other stakeholders about the CMS' national coverage analysis for implantable cardioverter defibrillators, with several suggesting that the Coverage with Evidence Development requirement for the devices is unnecessary. "It is critical that CMS reassess the rationale for this data-collection requirement in the 2005 NCD and make a determination based on the evidence collected to date," AdvaMed said, noting that a registry has been in place for 12 years and collected data on more than 1 million patients already.
AdvaMed comments on Medicare coverage for ICDs
Sign up for AdvaMed SmartBrief
Medical technology news
Get the intelligence you need: news and information that is changing your industry today, hand-curated by our professional editors from thousands of sources and delivered straight to your inbox.